Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,162 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-Fluorouracil Clear all
Completed Phase 2 Interventional

S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer

NCT00003018
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dipyridamole, fluorouracil, leucovorin calcium, mitomycin C
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 25, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

NCT07290985
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Tislelizumab, Leucovorin, Oxaliplatin, Fluorouracil, Zanidatamab, Zolbetuximab
Drug
Lead sponsor
American Association for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT01619423
View directory record Official record
Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

NCT00337103
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin Mesylate, Capecitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
13
States / cities
Anaheim, California • La Verne, California • Poway, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Capecitabine in Treating Patients With Metastatic Breast Cancer

NCT00274768
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Annapolis, Maryland • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

NCT00004242
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 25, 2026, 5:21 AM EDT
Withdrawn Phase 3 Interventional

Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

NCT03536182
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
Carbon Ion Radiation Therapy (CIRT), Intensity Modulated Radiation Therapy (IMRT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

NCT02021422
View directory record Official record
Conditions
Pancreas Cancer
Interventions
anakinra, Oxaliplatin, Irinotecan, fluorouracil
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

NCT00890305
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
CT-011, FOLFOX
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Huntsville, Alabama • Tampa, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 25, 2026, 5:21 AM EDT
Not listed Phase 2 Interventional

Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer

NCT04672005
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Drug
Lead sponsor
Lyudmyla Berim
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Hamilton, New Jersey • Jersey City, New Jersey • Livingston, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 25, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

NCT01197664
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
paricalcitol, radiation therapy, laboratory biomarker analysis, fluorouracil
Drug · Radiation · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer

NCT00307736
View directory record Official record
Conditions
Rectal Cancer, Adenocarcinoma of the Rectum
Interventions
5-fluorouracil, bevacizumab, erlotinib, External beam radiation therapy (EBRT)
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed

NCT00002593
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium, levamisole hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2005
U.S. locations
57
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 25, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

NCT07419464
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
Interventions
5-Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Withdrawn Phase 3 Interventional

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

NCT01327521
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
CyberKnife, TACE, CT Contrast, doxorubicin, Epirubicin, 5-fluorouracil, Mitomycin C, Gemcitabine, Cisplatin, SMANCS
Device · Procedure · Drug
Lead sponsor
Albert Koong
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis

NCT01783756
View directory record Official record
Conditions
Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
lapatinib ditosylate, everolimus, capecitabine, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

NCT02715531
View directory record Official record
Conditions
Solid Tumor
Interventions
5-FU, Atezolizumab, Bevacizumab, Gemcitabine, Leucovorin, Nab-Paclitaxel, Oxaliplatin, Capecitabine, Cisplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 25, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional

FOLFIRINOX + NIS793 in Pancreatic Cancer

NCT05417386
View directory record Official record
Conditions
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions
FOLFIRINOX, Oxaliplatin, Leucovorin, Irinotecan, 5-Fluorouracil (5-FU), NIS793, Chemoradiation, Capecitabine, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
Colin D. Weekes, M.D., PhD
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 25, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional

sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)

NCT05332002
View directory record Official record
Conditions
Gastro-Intestinal Cancer
Interventions
Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Hamilton, New Jersey • Lakewood, New Jersey • Long Branch, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Not yet recruiting Phase 2 Interventional

Utilizing Standard of Care Induction Chemotherapy Followed by MR-LINAC Radiotherapy and Surgical Exploration to Improve Resectability Rates in Potentially Resectable Locally Advanced Pancreatic Cancer

NCT07871461
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Induction Chemotherapy - FOLFIRINOX, Induction Chemotherapy - Gemcitabine and Nab-Paclitaxel, MR-LINAC Guided Radiotherapy, Surgical Exploration and Resection
Drug · Radiation · Procedure
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NCT02135042
View directory record Official record
Conditions
EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7
Interventions
Bone Scan, Cisplatin, Clinical Observation, Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Quality-of-Life Assessment
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
197
States / cities
Birmingham, Alabama • Tucson, Arizona • Auburn, California + 150 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

NCT03281369
View directory record Official record
Conditions
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions
5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
Drug · Biological
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma

NCT01498783
View directory record Official record
Conditions
Central Nervous System Malignancies, Ependymoma
Interventions
5-fluorouracil
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 25, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

NCT03734029
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan (DS-8201a), Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
38
States / cities
Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 5:21 AM EDT